Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

51P - Shortcomings of immuno oncology (IO) agents application into real-world practise due to financial constraints in a resource constrained setting

Date

09 Dec 2020

Session

e-Poster Display Session

Presenters

Goteti Sharat Chandra

Citation

Annals of Oncology (2020) 31 (suppl_7): S1428-S1440. 10.1016/annonc/annonc391

Authors

G. Sharat Chandra1, M. Singhal2, S. Valame2, A. Sharma2

Author affiliations

  • 1 Medical Oncology, Indraprastha Apollo Hospital, 110076 - New Delhi/IN
  • 2 Indraprastha Apollo Hospital, New Delhi/IN
More

Abstract 51P

Background

Indications of IO have been on the rise with growing data across different cancers ranging from metastatic to earlier stages. However, applicability of the same into real world practise is limited in lower middle income countries due to financial constraints. Data is lacking in this regard.

Methods

We conducted an observational study at our center to see applicability of IO indications across different cancers. Consecutive patients between Jan 2018 and Feb 2020 who had an indication for IO usage were enrolled and their treatment regimens studied. Patients across different primary sites were included with approved IO regimen .Reasons for non usage of IO were studied.

Results

Between Jan 2018 and Feb 2020 ,374 patients were enrolled who were eligible for treatment with IO either as a single agent or as combination .The most common indication was metastatic NSCLC (22.4%),head & neck (17.1%),RCC (11.2%) ,bladder (10.1%), endometrium (9.6%) ,HCC (10.1%) ,Hodgkins lymphoma (4.2%),melanoma (3.7 %) stage 3 NSCLC (5.3%) and so on .Of 374 patients ,only 114 (30.4%) were finally treated with IO regimen .The most common reason for non usage was financial constraints (80.7%) which included exhaustion of insurance limit ,denial by insurance company (11.5%) and non availability of drug (7.6%) .Of the 114 patients who were treated ,26.3% had to withdraw the drug owing to financial toxicity while the disease was still responding with the median time to withdrawal being 6.4 months.

Conclusions

Our study depicts a real-world picture of practical difficulties in treating with approved regimens with financial constraints leading to non usage/withdrawal of drug in nearly 65% patients. This issue needs to be addressed if more patients are to be benefitted from IO agents in the future in lower middle income countries like India.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.